ImmunoVec is a biotechnology company with a novel platform using DNA-loaded polymeric nanoparticles to precisely reprogram cells in patients, offering the potential to reset the immune system and transform treatment for life-threatening autoimmune diseases, solid tumors, and genetic disorders. The company’s proprietary platform combines synthetic, cell type-specific promoters across multiple delivery vehicles to enable precise and durable expression of therapeutic payloads within targeted cells. ImmunoVec is headquartered in Los Angeles.
| Website | https://www.immunovec.com/ |
| Employees | 13 (8 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Cancer Immunotherapy, Immunotherapy, Immuno-Oncology, Immuno Oncology, Viral Vectors, Precision Medicine, Viral Therapeutics, Gene Therapy, Targeted Therapy, Cancer Vaccines, Therapeutic Vaccines, Clinical Trials, Drug Development, Cancer Treatment, Cancer Research, Novel Therapeutics, Biotechnology, Pharmaceutical |
| Competitors | Atreca, Inc., Eisai Co., Ltd., Adagio Therapeutics, Lengo Therapeutics, ImmunoGen, Inc., Aduro Biotech is now Chinook Therapeutics, Spectrum Pharmaceuticals, Sorrento Therapeutics, Inc., MedImmune, CureVac +38 more (view full list) |
Looking for a particular ImmunoVec employee's phone or email?
Ryan Wong is the CEO of ImmunoVec.
8 people are employed at ImmunoVec.
ImmunoVec is based in Los Angeles, California.